Browse by Administration Route
This page shows data for Percutaneous virus.
Total
Entries Retrieved: 2
| ID | Vaccine Name | Disease Name | Disease Classification | Virus Name | Nucleic Acid Content | Vaccine Type | Vaccine Status | Manufacturer | Year of Manufacturing | Manufacturing Country | Age | Dosage | Administration Route | Adjuvant | Target Strain | Description | Approving Organisation | Collaborating Organisation | Other Countries | Trade Name | PMID | Clinical Trial ID | Reference Link | Additional Links |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10131 | ACAM2000 | Smallpox | Exanthous | Variola virus | double stranded DNA | Live-attenuated | Approved | Emergent BioSolutions | 2003 | USA | Below 12 months of age | Single dose | Percutaneous | NA | Recombinant vaccinia viruses derived from replication-competent vaccinia strain | Lyophilized | US FDA | NA | NA | NA | NA | NA | https://www.fda.gov/vaccines-blood-biologics/vaccines/acam2000 | NA |
| 10133 | Aventis Pasteur Smallpox Vaccine | Smallpox | Exanthous | Variola virus | double stranded DNA | Live-attenuated | Approved | National Institute of Allergy and Infectious Diseases | 2010 | USA | 18 - 32 years | NA | Percutaneous | NA | NA | NA | US FDA | NA | NA | NA | NA | NCT00038987 | https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/smallpox-preparedness-and-response-updates-fda | https://clinicaltrials.gov/ct2/show/NCT00038987 |